Alexandre Coimbra1, Dai Feng2, Sonia Apreleva2, Peter Hu3, S Ramana4, A. Bernstein5, Matthias Guenther6, William Cho7, Mark Forman8, Ajay Verma9, Gary Herman10, Richard Baumgartner2, David Feinberg4
1Imaging, Merck & Co, Inc, West Point, PA, United States; 2Biometrics, Merck & Co, Inc, Rahway, NJ, United States; 3BARDS, Merck & Co, Inc, Upper Gwynedd, PA, United States; 4Advanced MRI Technologies, Sebastopol, CA, United States; 5Redwood Regional Medical Group, Santa Rosa, CA, United States; 6Fraunhofer MEVIS-Institute for Medical Image Computing, Bremen, Germany; 7Experimental Medicine, Merck & Co, Inc, Upper Gwynedd, PA, United States; 8Clinical Pharmacology, Merck & Co, Inc, Upper Gwynedd, PA, United States; 9Translational Neurology, Biogen Idec, Cambridge, MA, United States; 10Clinical Research, Merck & Co, Inc, Rahway, NJ, United States
In this contribution we assessed the test-retest reproducibility of 3D GRASE ASL technique at 1.5 T and in populations of AD patients and age matched control. Assessment of measurement reproducibility was done using graphical methods as well as quantitative metrics such as Intraclass Correlation Coefficient and within subject coefficient of variability. Our findings suggest that the test-retest reproducibility varies between ROIs, and overall moderate to very good reproducibility can be achieved. Assessment of reproducibility is an important first step to inform design (e.g. parallel versus cross-over) of future studies of disease progression and treatment effect.